Comparison

suvorexant-mk-4305

Item no. V1306-50mg
Manufacturer InvivoChem LLC
CASRN 1030377-33-3
Amount 50 mg
Quantity options 100 mg 10 mg 250 mg 25 mg 5 mg
Category
Type Biochemicals
Specific against other
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Available
Description
InvivoChem Cat #:V1306CAS #:1030377-33-3Purity >=98%

Description: This is a DEA controlled substance schedule IV Suvorexant (also known as MK-4305) is a potent dual OX receptor antagonist with Ki of 0.55 nM and 0.35 nM for OX1 receptor and OX2 receptor, respectively. Suvorexant is developed by Merck for the treatment of insomnia. It is currently undergoing Phase III trials. Suvorexant works by turning off wakefulness rather than by inducing sleep. As a dual orexin receptor (OXR) antagonist (DORA), suvorexant (MK-4305) has shown promise for the treatmen to finsomnias and sleep disorders.

Description: This is a DEA controlled substance schedule IV his is a DEA controlled substance schedule IV

References: J Med Chem. 2010 Jul 22; 53(14):5320-32; Br J Pharmacol. 2014 Jan; 171(2):351-63.

References:
Molecular Weight (MW)
450.92
Formula
C23H23ClN6O2
CAS No.
1030377-33-3
Storage
-20C for 3 years in powder form
-80C for 2 years in solvent
Solubility (In vitro)
DMSO: 10 mg/mL (22.2 mM)
Water: < 1 mg/mL
Ethanol: < 1 mg/mL
Solubility (In vivo)
4% DMSO+10% PEG 400+10% Tween 80: 5mg/mL
Synonyms
MK4305; MK 4305; MK-4305

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 50 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close